ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025
Nuclear Imaging Strategies to Evaluate Cytokine Production in Autoimmune, Inflammatory, and Neoplastic Diseases: A Review of Current Preclinical Research.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cytokines are small proteins that directly regulate immune cell proliferation and signaling. An improved understanding of cytokine expression in specific microenvironments provides critical insights into essential physiologic and pathophysiologic responses to disease and infection. Standard methods used to detect and quantify cytokines are not fully suitable for this purpose, given their limited sensitivity and capacity to address cytokine heterogeneity and short biologic half-lives. In contrast, nuclear imaging modalities (e.g., PET, SPECT) can be used to detect cytokine binding in situ in real time. In this review, we discuss some of the most promising preclinical nuclear imaging agents that have been developed to target specific cytokines. These agents may ultimately be used in the clinical setting to monitor disease progression and responses to treatments for cancer and autoimmune and inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.